Dive into what's in store for #biopharma and #medtech, and what factors could drive innovation in Deloitte's 2024 Health Care and Life Sciences Outlook article. Read it here: https://bit.ly/48cltwL via Deloitte
BioPhase’s Post
More Relevant Posts
-
Thoughts on this? >> GAO directs ARPA-H to finalize plan for handling duplicate research >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #healthcare #pharmaceutical #pharma
GAO directs ARPA-H to finalize plan for handling duplicate research
https://endpts.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> GAO directs ARPA-H to finalize plan for handling duplicate research >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical
GAO directs ARPA-H to finalize plan for handling duplicate research
https://endpts.com
To view or add a comment, sign in
-
How do you improve health equity and diversity in pharmaceutical research?
Improving Health Equity and Diversity in Research
www2.deloitte.com
To view or add a comment, sign in
-
New business models are shaking up the healthcare market. This new article breaks down the GLP-1 Market using a drug manufacturer and digital services provider to cover the entire episode of care. Well done Daniel Maley Dylan Reid(Moskowitz) Robert Horne The Alliance for Artificial Intelligence in Healthcare (AAIH) https://lnkd.in/ehnm7q4m
Aligning Incentives in Healthcare Through Tech and Science: The Dario Health and Sanofi Collaboration — Forest Hill Labs: A Unique Healthcare Consultancy
foresthilllabs.net
To view or add a comment, sign in
-
This article dissects the nuanced ways in which drug companies may manipulate trial results 🤔 Essential reading for healthcare professionals navigating the complexities of research integrity... What do you think? #ClinicalTrials #ResearchIntegrity #HealthcareEthics
How to spot when drug companies spin clinical trial results
https://www.statnews.com
To view or add a comment, sign in
-
📚 Dive into the latest research on Pharmacogenomics (PGx) testing! 📚 In their article, David and co-workers explored the transformative impact of PGx testing on hospital admissions and medication changes (David et al.). 🔍 Comparing data between PGx tested patients and those receiving standard treatment, the study found some groundbreaking results! 💊 Not only did medication changes happen more frequently with PGx-guided treatment, but hospitalizations were also significantly lower. 📉 This sheds light on the immense benefits PGx-guided drug prescription brings to patients' well-being. 💡 This research underscores the potential of PGx in revolutionizing healthcare practices. 💡 It also points out important opportunities and evidence gaps crucial for the integration of PGx into health systems. https://loom.ly/IEjYCLA 🌟 Stay tuned for more updates as we continue to explore the forefront of personalized medicine with Genetix! 🌟 #Pharmacogenomics #HealthcareInnovation #GenetixResearch #PersonalizedMedicine
To view or add a comment, sign in
-
-
Ever wondered if you have used an industry term correctly? Keeping up with all the healthcare/biopharma terminology can be overwhelming. Check out this article for a refresh.
BioPharma or Biologics: Top 6 Industry Terms Defined | Oliver Design
https://oliverdesign.com
To view or add a comment, sign in
-
EVA pharma (Egypt) & Eli Lilly and Company co-hosted a powerful panel at the #WorldHealthAssembly highlighting the power of partnerships to accelerate access, affordability, and quality of essential #NCD (non-communicable disease) medications. The rise of NCDs like #cardiovasculardiseases #diabetes & #cancer poses a critical global challenge. Additionally, LMICs (low- and middle-income countries) often face significant hurdles in providing these life-saving medications to their populations. The solution is collaborative efforts! Partnerships between pharmaceutical companies, governments & global organizations can drive innovation in manufacturing, streamline regulations, and strengthen healthcare systems in LMICs. EVA pharma & Eli Lilly and Company are committed in their ongoing collaboration to provide high-quality, affordable insulin to millions in Egypt and across Africa. What steps can we take to ensure everyone has access to the medications they need? #WorldHealthAssembly #GlobalHealth #AccessToMedicine #NCD #AfricaCDC #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #PartnerIdentification #BusinessDevelopment #Licensing Detailed News: https://lnkd.in/gDukR9Zp Follow our page for more industry updates: https://lnkd.in/de5zNWmK
WORLD HEALTH ASSEMBLY - LIFE SCIENCES: Panel on Fostering Effective Local Manufacturing Partnerships to Improve Access to NCD Medicines
https://bciu.zohobackstage.com/FosteringEffectiveLocalManufacturingPartnershipstoImproveAccesstoNCDM
To view or add a comment, sign in
-
How can Andaman7 help with drug management - in care or research settings? Check the presentation at the EHTEL - Collaborating for Digital Health and Care in Europe Thought Leader Symposium. More info and download his presentation: https://bit.ly/a7esp23
[Session 3b] Medicines data integration for clinical use: New implementation patterns - European eHealth Multidisciplinary Stakeholder Platform
ehtel.eu
To view or add a comment, sign in
-
Eva Pharma & Eli Lilly's ongoing collaboration to provide affordable insulin in Egypt and Africa exemplifies the positive impact of such partnerships. In a first for Lilly, they're supplying their active pharmaceutical ingredient (API) for insulin at a significantly reduced price to Eva Pharma. This will allow Eva Pharma to formulate, fill, and finish insulin vials and cartridges in Africa, making them a trusted manufacturer of these life-saving products. Eva Pharma expects to reach an incredible one million people per year by 2030. This aligns perfectly with Lilly's 30x30 initiative, which aims to improve healthcare access for 30 million people in limited-resource settings annually by 2030.
EVA pharma (Egypt) & Eli Lilly and Company co-hosted a powerful panel at the #WorldHealthAssembly highlighting the power of partnerships to accelerate access, affordability, and quality of essential #NCD (non-communicable disease) medications. The rise of NCDs like #cardiovasculardiseases #diabetes & #cancer poses a critical global challenge. Additionally, LMICs (low- and middle-income countries) often face significant hurdles in providing these life-saving medications to their populations. The solution is collaborative efforts! Partnerships between pharmaceutical companies, governments & global organizations can drive innovation in manufacturing, streamline regulations, and strengthen healthcare systems in LMICs. EVA pharma & Eli Lilly and Company are committed in their ongoing collaboration to provide high-quality, affordable insulin to millions in Egypt and across Africa. What steps can we take to ensure everyone has access to the medications they need? #WorldHealthAssembly #GlobalHealth #AccessToMedicine #NCD #AfricaCDC #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #PartnerIdentification #BusinessDevelopment #Licensing Detailed News: https://lnkd.in/gDukR9Zp Follow our page for more industry updates: https://lnkd.in/de5zNWmK
WORLD HEALTH ASSEMBLY - LIFE SCIENCES: Panel on Fostering Effective Local Manufacturing Partnerships to Improve Access to NCD Medicines
https://bciu.zohobackstage.com/FosteringEffectiveLocalManufacturingPartnershipstoImproveAccesstoNCDM
To view or add a comment, sign in